NCT03801915View on ClinicalTrials.gov

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 13, 2019

Primary Completion Date

May 27, 2022

Study Completion Date

May 27, 2022

Conditions

Colon CancerPancreatic CancerCholangiocarcinomaMetastatic Colon CarcinomaLiver Metastasis

Interventions

DRUG

MVT-5873

1 mg/kg or 3 mg/kg for pre-operative dose, 1 mg/kg during post-operative period

PROCEDURE

pancreatectomy or hepatectomy

Pancreatectomy or hepatectomy

Trial Locations (1)

20892

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT03801915 - Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers | Biotech Hunter | Biotech Hunter